Clinical trial · Observational
Multiple Myeloma Prognostic Indices
Spectrum of Blood Viscosity , Albumin / Fibrinogen Ratio and Red Cell Distribution Width in Newly Diagnosed Multiple Myeloma Patients. Observation Study
NCT06095752CI-TRIAL-00096184completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study was to evaluate the impact of albumin / fibrinogen ratio, blood viscosity and RDW on the prognosis of a newly diagnosed MM patients
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Diseases | — | UNRESOLVED | — |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood viscosity , albumin / fibrinogen ratio and red cell distribution | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Determine the prognosis of newly diagnosed multiple myeloma patients in survival for one year.
- timeFrame
- One year
- description
- After initial diagnosis of a patient to have multiple myeloma , blood viscosity is obtained and within a year , a relation is established between the prognosis of the disease and the initial results of blood viscosity
- measure
- Determine the prognosis of newly diagnosed multiple myeloma patients in survival for one year.
- timeFrame
- One year
- description
- After initial diagnosis of a patient to have multiple myeloma , albumin / fibrinogen ratio is obtained and within a year , a relation is established between the prognosis of the disease and the initial results of albumin /fibrinogen ratio
- measure
- Determine the prognosis of newly diagnosed multiple myeloma patients in survival for one year.
- timeFrame
- One year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients newly diagnosed with MM according to International Myeloma Working Group criteria 2016. Exclusion Criteria: * Patient previously diagnosed MM and started treatment or in post treatment follow up
References
Publications (0)
Data not yet available
No reference posted for this study.